Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1852-1862

  Euhus, David ^a   Bu, Dawei ^a   Xie, Xian Jin ^b   Sarode, Venetia ^a   Ashfaq, Raheela ^a   Hunt, Kelly ^c   Xia, Weiya ^c   O'Shaughnessy, Joyce ^d   Grant, Michael ^e   Arun, Banu ^c   Dooley, William ^f   Miller, Alexander ^g   Flockhart, David ^h   Lewis, Cheryl ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g University of Texas Health Science Center at San Antonio   (United States)

^h INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYTOCHROME P450 2D6; DNAJC12 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PLACEBO; SOMATOMEDIN; TAMOXIFEN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR ETV5; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BLOOD SAMPLING; BREAST CANCER; BREAST EPITHELIUM; CANCER PREVENTION; CANCER RISK; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MORPHOMETRICS; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ADENOVIRUS E1A PROTEINS; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOPSY, FINE-NEEDLE; BREAST; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL PROLIFERATION; DNA METHYLATION; DNA-BINDING PROTEINS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 81555195404     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0186     Document Type: Article

References (50)

1. Fisher B, Constantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Bowel and Breast Project P-1 study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
2. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga AAR, Sandri MT, Cazzaniga M, et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 2001;69:21-7. (Pubitemid 33079026)
3. Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lonning PE. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996;69: 335-9. (Pubitemid 26298301)
4. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, et al. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009;27:3749-56.
5. Decensi A, Formelli F, Torrisi R, Costa A. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biochem Suppl 1993;17G:226-33.
6. Fabian CJ. Surrogate response biomarkers in prevention research: do they point the way or lead us astray? J Clin Oncol 2009;27:3734-6.
7. Navarrete MA, Maier CM, Falzoni R, Quadros LG, Lima GR, Baracat EC, et al. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005;7:R306-13.
8. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11: 166-72. (Pubitemid 40081117)
9. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:1051-9.
10. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92:1217-27. (Pubitemid 30627730)
11. Russo J, Romero AL, Russo IH. Architectural pattern of the normal and cancerous breast under the influence of parity. Cancer Epidemiol Biomark Prev 1994;3:219-24. (Pubitemid 24172534)
12. McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, et al. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 2009;27:5893-8.
13. Endogenous Hormones Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev 2003;12:1457-61.
14. Masood S, Fryberg ER, McLellan GL, Dee S, Bullard JB. Cytologic differentiation between proliferative and non-proliferative breast disease in mammographically guided fine-needle aspirates. Diagn Cytopathol 1991;7:581-90.
15. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52. (Pubitemid 38856915)
16. Euhus DM, Bu D, Ashfaq R, Xie XJ, Bian A, Leitch AM, et al. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1812-21. (Pubitemid 47450511)
17. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
18. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
19. Slonim DK, Tamayo P, Mesirov JP, Golub TR, Lander ES. Class prediction and discovery using gene expression data [abstract]. In: Proceedings of the Fourth International Conference on Computational Molecular Biology; 2000 Apr 8-11; RECOMB: Tokyo, Japan.
20. Bieche I, Tozlu S, Girault I, Onody P, Driouch K, Vidaud M, et al. Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 2004;25:405-11. (Pubitemid 38351094)
21. Chotteau-Lelievre A, Revillion F, Lhotellier V, Hornez L, Desbiens X, Cabaret V, et al. Prognostic value of ERM gene expression in human primary breast cancers. Clin Cancer Res 2004;10:7297-303. (Pubitemid 39487718)
22. Ishida S, Higashino F, Aoyagi M, Takahashi A, Suzuki T, Shindoh M, et al. Genomic structure and promoter activity of the E1AF gene, a member of the ETS oncogene family. Biochem Biophys Res Commun 2006;339:325-30. (Pubitemid 41697553)
23. Tyagi G, Carnes K, Morrow C, Kostereva NV, Ekman GC, Meling DD, et al. Loss of Etv5 decreases proliferation and RET levels in neonatal mouse testicular germ cells and causes an abnormal first wave of spermatogenesis. Biol Reprod 2009;81:258-66.
24. Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, Kaneko E, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature moleculemarked MSC in bone marrow by immunohistochemistry. Genes Cells 2009;14:407-24.
25. Chen C, Ouyang W, Grigura V, Zhou Q, Carnes K, Lim H, et al. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 2005;436:1030-4. (Pubitemid 41191687)
26. Chotteau-Lelievre A, Montesano R, Soriano J, Soulie P, Desbiens X, deLaunoit Y. PEA3 transcription factors are expressed in tissues undergoing branching morphogenesis and promote formation of duct-like structures by mammary epithelial cells in vitro. Dev Biol 2003;259:241-57. (Pubitemid 36836143)
27. Kurpios NA, Sabolic NA, Shepherd TG, Fidalgo GM, Hassell JA. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 2003;8:177-90. (Pubitemid 38129940)
28. Chotteau-Lelievre A, Desbiens X, Pelczar H, Defossez PA, de Launoit Y. Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. Oncogene 1997; 15:937-52. (Pubitemid 27399555)
29. Kurpios NA, MacNeil L, Shepherd TG, Gludish DW, Giacomelli AO, Hassell JA. The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development. Dev Biol 2009;325:106-21.
30. Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S, Fujinaga K. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996;12:221-7. (Pubitemid 26042559)
31. Firlej V, Ladam F, Brysbaert G, Dumont P, Fuks F, de Launoit Y, et al. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J Cell Sci 2008;121:3393-402.
32. Richard V, Rosol TJ, Foley J. PTHrP gene expression in cancer: do all paths lead to Ets? Crit Rev Eukaryot Gene Expr 2005;15:115-32. (Pubitemid 41277407)
33. Baker KM, Wei G, Schaffner AE, Ostrowski MC. Ets-2 and components of mammalian SWI/SNF form a repressor complex thatnegatively regulates the BRCA1 promoter. J Biol Chem 2003;278: 17876-84. (Pubitemid 36799393)
34. Li QJ, Yang SH, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M. MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J 2003;22:281-91. (Pubitemid 36119434)
35. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99: 1695-705. (Pubitemid 351767220)
36. Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, et al. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol 2009;144:696-704.
37. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 2004;90:1216-21. (Pubitemid 38496816)
38. Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005;26:977-84.
39. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004;279: 48319-28. (Pubitemid 39540988)
40. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA. A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One 2008;3:e2572.
41. Sun J, Nawaz Z, Slingerland JM. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Mol Endocrin 2007;21:2651-62. (Pubitemid 350035148)
42. Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004;5:R66.
43. Rae J, Johnson M, Scheys J, Cordero K, Larios J, Lippman M. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 2005;92:141-9. (Pubitemid 40933578)
44. Da Silva ID, Dias-Netto E, Villanova FE, Yamamoto L, Baracat EC, Lima GR, et al. Tamoxifen down-regulates CaMKII messenger RNA levels in normal human breast tissue. Clin Exp Obstet Gynecol 2004;31:204-8. (Pubitemid 39297402)
45. Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, et al. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 2008;17: 1884-90.
46. Bernardes JR Jr, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 1999;67:33-8. (Pubitemid 29495979)
47. deSousa JA, de Seixas MT, de Lima GR, Baracat EC, Gebrim LH. Evaluation of monoclonal antibody MIB-1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen. Breast J 2001;7:392-7. (Pubitemid 34024461)
48. deLima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003;39:891-8. (Pubitemid 36428620)
49. Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 1991;64:764-8.
50. Meggiorini ML, Labi L, Vestri AR, Porfiri LM, Savelli S, De Felice C. Tamoxifen in women with breast cancer and mammographic density. Eur J Gynaecol Oncol 2008;29:598-601.